- Home
- HEES vs RYTM Comparison
HEES vs RYTM Comparison
Compare HEES & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEES
- RYTM
- Stock Information
- Founded
- HEES 1961
- RYTM 2008
- Country
- HEES United States
- RYTM United States
- Employees
- HEES N/A
- RYTM N/A
- Industry
- HEES Misc Corporate Leasing Services
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- HEES Industrials
- RYTM Health Care
- Exchange
- HEES Nasdaq
- RYTM Nasdaq
- Market Cap
- HEES 3.3B
- RYTM 3.8B
- IPO Year
- HEES 2006
- RYTM 2017
- Fundamental
- Price
- HEES $91.97
- RYTM $57.38
- Analyst Decision
- HEES
- RYTM Strong Buy
- Analyst Count
- HEES 0
- RYTM 12
- Target Price
- HEES N/A
- RYTM $75.42
- AVG Volume (30 Days)
- HEES 716.3K
- RYTM 671.0K
- Earning Date
- HEES 04-29-2025
- RYTM 05-07-2025
- Dividend Yield
- HEES 1.19%
- RYTM N/A
- EPS Growth
- HEES N/A
- RYTM N/A
- EPS
- HEES 2.49
- RYTM N/A
- Revenue
- HEES $1,464,681,000.00
- RYTM $136,863,000.00
- Revenue This Year
- HEES $4.58
- RYTM $43.84
- Revenue Next Year
- HEES $6.68
- RYTM $65.62
- P/E Ratio
- HEES $37.08
- RYTM N/A
- Revenue Growth
- HEES N/A
- RYTM 48.88
- 52 Week Low
- HEES $40.92
- RYTM $35.17
- 52 Week High
- HEES $101.28
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- HEES 54.83
- RYTM 43.00
- Support Level
- HEES $89.86
- RYTM $62.69
- Resistance Level
- HEES $90.93
- RYTM $65.53
- Average True Range (ATR)
- HEES 0.97
- RYTM 3.04
- MACD
- HEES 0.28
- RYTM -0.73
- Stochastic Oscillator
- HEES 84.76
- RYTM 1.14
About HEES H&E Equipment Services Inc.
H&E Equipment Services Inc is an integrated equipment services company. The Company's construction rental fleet is among the industry's youngest with an equipment mix comprised of aerial work platforms, earthmoving, material handling, and other general and specialty lines. It rents, sells, and provides parts and services support for four core categories of equipment including hi-lift or aerial work platform equipment, cranes, earthmoving equipment, and industrial lift trucks. It engages in five principal business activities: equipment rentals; new equipment sales; sales of rental equipment; parts sales; and services. The majority of its revenue is derived from the equipment rentals segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.